Status:
RECRUITING
PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in NSCLC
Lead Sponsor:
University Hospital, Angers
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Solid cancers and their therapeutic management remain a major public health problem due to their increasing prevalence and associated mortality. Among solid cancers, lung cancer ranks 4th among incide...
Eligibility Criteria
Inclusion
- 18 years or more
- patient with NSCLC
- pembrolizumab treatment (monotherapy or not) with a placed line (peripheral catheter, PICC or implantable port)
Exclusion
- objection to participate in the study
- patient under judicial protection
Key Trial Info
Start Date :
December 17 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2028
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT06195527
Start Date
December 17 2025
End Date
June 1 2028
Last Update
January 6 2026
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Angers University Hospital
Angers, France, 49000
2
CH Le Mans
Le Mans, France, 53000